Roberts, Glore & Co’s Pfizer PFE Stock Holding History

Roberts, Glore & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$948K	Buy	39,351 +461	+1%	+$12.1K	0.23%	92
2026 Q1	$1.09M	Sell	38,890 -3,765	-9%	-$100K	0.3%	77
2025 Q4	$1.06M	Buy	42,655 +2,713	+7%	+$68.4K	0.28%	81
2025 Q3	$1.02M	Buy	39,942 +1,282	+3%	+$31.6K	0.28%	83
2025 Q2	$937K	Sell	38,660 -4,216	-10%	-$98.3K	0.27%	89
2025 Q1	$1.09M	Buy	42,876 +1,883	+5%	+$49.3K	0.33%	72
2024 Q4	$1.09M	Buy	40,993 +1,649	+4%	+$44.7K	0.32%	74
2024 Q3	$1.14M	Sell	39,344 -182	-0.5%	-$5.31K	0.33%	76
2024 Q2	$1.11M	Buy	39,526 +6,823	+21%	+$188K	0.33%	76
2024 Q1	$908K	Buy	32,703 +5,319	+19%	+$148K	0.27%	87
2023 Q4	$788K	Buy	27,384 +14,135	+107%	+$427K	0.25%	91
2023 Q3	$439K	Buy	13,249 +710	+6%	+$25.1K	0.15%	121
2023 Q2	$460K	Buy	12,539 +45	+0.4%	+$1.75K	0.15%	120
2023 Q1	$510K	Buy	12,494 +642	+5%	+$27.7K	0.17%	113
2022 Q4	$607K	Buy	11,852 +50	+0.4%	+$2.4K	0.21%	101
2022 Q3	$516K	Sell	11,802 -100	-0.8%	-$4.86K	0.18%	107
2022 Q2	$624K	Sell	11,902 -100	-0.8%	-$5.1K	0.21%	100
2022 Q1	$621K	Sell	12,002 -1,266	-10%	-$65.7K	0.18%	111
2021 Q4	$783K	Sell	13,268 -52	-0.4%	-$2.58K	0.21%	97
2021 Q3	$572K	Sell	13,320 -3,030	-19%	-$134K	0.17%	110
2021 Q2	$640K	Sell	16,350 -712	-4%	-$27.7K	0.19%	107
2021 Q1	$618K	Buy	17,062 +1,200	+8%	+$42.6K	0.19%	108
2020 Q4	$584K	Sell	15,862 -1,015	-6%	-$37.2K	0.19%	110
2020 Q3	$587K	Sell	16,877 -52	-0.3%	-$1.82K	0.21%	105
2020 Q2	$525K	Sell	16,929 -143	-0.8%	-$4.86K	0.21%	101
2020 Q1	$528K	Sell	17,072 -210	-1%	-$7.16K	0.23%	92
2019 Q4	$642K	Buy	17,282 +3,048	+21%	+$109K	0.25%	91
2019 Q3	$485K	Buy	14,234 +142	+1%	+$5.16K	0.3%	83
2019 Q2	$579K	Hold	14,092	–	–	0.35%	76
2019 Q1	$568K	Buy	14,092 +369	+3%	+$14.8K	0.36%	76
2018 Q4	$568K	Hold	13,723	–	–	0.4%	73
2018 Q3	$574K	Sell	13,723 -1,054	-7%	-$40.6K	0.33%	85
2018 Q2	$509K	Hold	14,777	–	–	0.31%	89
2018 Q1	$498K	Buy	14,777 +565	+4%	+$19.4K	0.31%	86
2017 Q4	$488K	Sell	14,212 -685	-5%	-$23.4K	0.3%	86
2017 Q3	$505K	Sell	14,897 -316	-2%	-$10.2K	0.33%	82
2017 Q2	$485K	Hold	15,213	–	–	0.32%	83
2017 Q1	$494K	Sell	15,213 -492	-3%	-$15.5K	0.34%	80
2016 Q4	$484K	Buy	15,705 +359	+2%	+$11K	0.34%	81
2016 Q3	$493K	Hold	15,346	–	–	0.35%	81
2016 Q2	$513K	Hold	15,346	–	–	0.39%	74
2016 Q1	$432K	Sell	15,346 -378	-2%	-$10.8K	0.33%	82
2015 Q4	$482K	Buy	15,724 +975	+7%	+$30.7K	0.36%	78
2015 Q3	$440K	Hold	14,749	–	–	0.34%	81
2015 Q2	$469K	Sell	14,749 -1,080	-7%	-$35.2K	0.33%	81
2015 Q1	$522K	Sell	15,829 -712	-4%	-$22.6K	0.36%	74
2014 Q4	$489K	Sell	16,541 -791	-5%	-$22.7K	0.33%	78
2014 Q3	$486K	Hold	17,332	–	–	0.34%	75
2014 Q2	$488K	Sell	17,332 -402	-2%	-$11.5K	0.33%	77
2014 Q1	$540K	Sell	17,734 -465	-3%	-$13.9K	0.37%	77
2013 Q4	$529K	Sell	18,199 -1,898	-9%	-$55.2K	0.37%	76
2013 Q3	$548K	Sell	20,097 -1,710	-8%	-$46.5K	0.4%	69
2013 Q2	$580K	Buy	+21,807	New	+$603K	0.36%	75

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Roberts, Glore & Co's PFE Position: Q2 2026 in Review

Roberts, Glore & Co increased its Pfizer (PFE) stake by 1.2% in Q2 2026, buying an estimated $12.1K and bringing the position to 39,351 shares worth $948K. The position accounts for 0.23% of the portfolio, ranked #92.

Roberts, Glore & Co first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.14M in Q3 2024. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Roberts, Glore & Co held 39,351 shares of Pfizer worth $948K as of Q2 2026.
Roberts, Glore & Co bought 461 Pfizer shares in Q2 2026, an estimated $12.1K.
Pfizer made up 0.23% of Roberts, Glore & Co's portfolio in Q2 2026, its #92 holding.
Roberts, Glore & Co first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Roberts, Glore & Co's Pfizer position peaked at $1.14M in Q3 2024.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Roberts, Glore & Co's 13F filing for Q2 2026, filed 11 Aug 2026.